Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Neonc Technologies Inc. is active in the Biotechnology & Pharmaceuticals technology area, where it currently manages 5 pending office actions. These actions are distributed across 5 distinct examiners, indicating that each application is receiving an independent review. This variety suggests that the company's prosecution strategy must address the different perspectives of multiple patent office officials.
The portfolio is also spread across 5 distinct art units, which reflects a range of technical claims within the biotechnology sector. BROWE, DAVID is identified as the busiest examiner for the company. However, this examiner is only responsible for 1 busiest examiner pending office action, which is the same volume handled by the other examiners involved in the company's current filings.
For a patent practitioner, the alignment of 5 pending office actions with 5 distinct art units suggests that the company's intellectual property is not concentrated in a single niche. Instead, the filings are broad enough to trigger review by multiple specialized divisions. Navigating this portfolio requires a multi-faceted approach, as the outcomes are distributed across several examiners rather than being centralized under BROWE, DAVID.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWE, DAVID | 1 | 26.7% | +28.0% |
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251839 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | BROWE, DAVID | 17d overdue |
| 17251452 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RODRIGUEZ, RAYNA B | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248733 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | LEE, HOI YAN NMN | 134d overdue |
| 18001082 | COMPOSITIONS AND METHODS FOR DELIVERING POLYNUCLEOTIDES | ZARA, JANE J | 118d overdue |
| 18251839 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | BROWE, DAVID | 17d overdue |
| 17251452 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RODRIGUEZ, RAYNA B | 55d |
| 17762878 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RAO, PADMAJA S | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1693 | 1 |
| 1637 | 1 |
| 1627 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18251839 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | BROWE, DAVID | 1617 | §103§112Other | Final Rejection | 17d overdue | Pending | May 04, 2023 |
| 18248733 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | LEE, HOI YAN NMN | 1693 | §103DP | Non-Final OA | 134d overdue | Pending | Apr 12, 2023 |
| 18001082 | COMPOSITIONS AND METHODS FOR DELIVERING POLYNUCLEOTIDES | ZARA, JANE J | 1637 | §103 | Final Rejection | 118d overdue | Pending | Dec 08, 2022 |
| 17762878 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RAO, PADMAJA S | 1627 | §103DP | Non-Final OA | — | Pending | Mar 23, 2022 |
| 17251452 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RODRIGUEZ, RAYNA B | 1628 | §102§103Other | Non-Final OA | 55d | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeonc Technologies Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
David Browe has the most, with 1 of Neonc Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
